Literature DB >> 25690588

The recent national lipid association recommendations: how do they compare to other established dyslipidemia guidelines?

Laura Flink1, James A Underberg, Jonathan D Newman, Eugenia Gianos.   

Abstract

The National Lipid Association (NLA) recently released recommendations for the treatment of dyslipidemias. These recommendations have commonalities and differences with those of other major societies with respect to risk assessment, lifestyle therapy, targets of therapy, and the use of non-statin agents. In this review, we compare the basic elements of the guidelines from each major society to provide clinicians with a comprehensive document reviewing the key principles of each.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25690588     DOI: 10.1007/s11883-015-0494-9

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN: 1523-3804            Impact factor:   5.113


  14 in total

1.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).

Authors: 
Journal:  JAMA       Date:  2001-05-16       Impact factor: 56.272

2.  Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

Authors: 
Journal:  Circulation       Date:  2002-12-17       Impact factor: 29.690

3.  2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

Authors:  Robert H Eckel; John M Jakicic; Jamy D Ard; Janet M de Jesus; Nancy Houston Miller; Van S Hubbard; I-Min Lee; Alice H Lichtenstein; Catherine M Loria; Barbara E Millen; Cathy A Nonas; Frank M Sacks; Sidney C Smith; Laura P Svetkey; Thomas A Wadden; Susan Z Yanovski
Journal:  J Am Coll Cardiol       Date:  2013-11-12       Impact factor: 24.094

4.  2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

Authors:  Neil J Stone; Jennifer G Robinson; Alice H Lichtenstein; C Noel Bairey Merz; Conrad B Blum; Robert H Eckel; Anne C Goldberg; David Gordon; Daniel Levy; Donald M Lloyd-Jones; Patrick McBride; J Sanford Schwartz; Susan T Shero; Sidney C Smith; Karol Watson; Peter W F Wilson; Karen M Eddleman; Nicole M Jarrett; Ken LaBresh; Lev Nevo; Janusz Wnek; Jeffrey L Anderson; Jonathan L Halperin; Nancy M Albert; Biykem Bozkurt; Ralph G Brindis; Lesley H Curtis; David DeMets; Judith S Hochman; Richard J Kovacs; E Magnus Ohman; Susan J Pressler; Frank W Sellke; Win-Kuang Shen; Sidney C Smith; Gordon F Tomaselli
Journal:  Circulation       Date:  2013-11-12       Impact factor: 29.690

5.  National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 - executive summary.

Authors:  Terry A Jacobson; Matthew K Ito; Kevin C Maki; Carl E Orringer; Harold E Bays; Peter H Jones; James M McKenney; Scott M Grundy; Edward A Gill; Robert A Wild; Don P Wilson; W Virgil Brown
Journal:  J Clin Lipidol       Date:  2014-07-15       Impact factor: 4.766

Review 6.  An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia.

Authors:  Scott M Grundy
Journal:  J Clin Lipidol       Date:  2013-10-22       Impact factor: 4.766

7.  Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis.

Authors:  S Matthijs Boekholdt; Benoit J Arsenault; Samia Mora; Terje R Pedersen; John C LaRosa; Paul J Nestel; R John Simes; Paul Durrington; Graham A Hitman; K M A Welch; David A DeMicco; Aeilko H Zwinderman; Michael B Clearfield; John R Downs; Andrew M Tonkin; Helen M Colhoun; Antonio M Gotto; Paul M Ridker; John J P Kastelein
Journal:  JAMA       Date:  2012-03-28       Impact factor: 56.272

8.  C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men.

Authors:  Paul M Ridker; Nina P Paynter; Nader Rifai; J Michael Gaziano; Nancy R Cook
Journal:  Circulation       Date:  2008-11-09       Impact factor: 29.690

9.  General cardiovascular risk profile for use in primary care: the Framingham Heart Study.

Authors:  Ralph B D'Agostino; Ramachandran S Vasan; Michael J Pencina; Philip A Wolf; Mark Cobain; Joseph M Massaro; William B Kannel
Journal:  Circulation       Date:  2008-01-22       Impact factor: 29.690

10.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.

Authors:  C Baigent; L Blackwell; J Emberson; L E Holland; C Reith; N Bhala; R Peto; E H Barnes; A Keech; J Simes; R Collins
Journal:  Lancet       Date:  2010-11-08       Impact factor: 79.321

View more
  5 in total

1.  Lipid-lowering drugs, dyslipidemia, and breast cancer risk in a Medicare population.

Authors:  Catherine Schairer; D Michal Freedman; Shahinaz M Gadalla; Ruth M Pfeiffer
Journal:  Breast Cancer Res Treat       Date:  2018-02-15       Impact factor: 4.872

2.  Association of prehypertension and cardiovascular risk factor clustering in Inner Mongolia: a cross-sectional study.

Authors:  Guoju Li; Guanghong Guo; Wenrui Wang; Ke Wang; Hailing Wang; Fen Dong; Yonggang Qian; Haiying Gong; Guodong Xu; Yanlong Li; Li Pan; Biao Zhang; Guangliang Shan
Journal:  BMJ Open       Date:  2017-06-30       Impact factor: 2.692

3.  Residual cardiovascular risk in patients who received lipid-lowering treatment in a real-life setting: retrospective study.

Authors:  Valentina Perrone; Diego Sangiorgi; Stefano Buda; Luca Degli Esposti
Journal:  Clinicoecon Outcomes Res       Date:  2016-10-25

Review 4.  Overview of guidelines for the management of dyslipidemia: EU perspectives.

Authors:  Vicente Giner-Galvañ; María José Esteban-Giner; Vicente Pallarés-Carratalá
Journal:  Vasc Health Risk Manag       Date:  2016-09-06

5.  N-3 polyunsaturated fatty acids improve lipoprotein particle size and concentration in Japanese patients with type 2 diabetes and hypertriglyceridemia: a pilot study.

Authors:  Kana Ide; Masaya Koshizaka; Hirotake Tokuyama; Takahiko Tokuyama; Takahiro Ishikawa; Yoshiro Maezawa; Minoru Takemoto; Koutaro Yokote
Journal:  Lipids Health Dis       Date:  2018-03-15       Impact factor: 3.876

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.